title: [Pharmacoepidemiologic investigations about the interactions between oral anticoagulants and other drugs in patients with hemostasis disorders].
abstract: OBJECTIVE
  To evaluate drugs interactions with oral anticoagulants and their clinical relevance, in patients from two emergency departments in hospital.
  
  
  METHODS
  Retrospective study, during one year, on patients (between 18 and 85 year old) with haemostatic disturbances admitted at two emergency departments in ,,Sf. Spiridon" Hospital, Iaşi and in Piatra Neamţ Public Hospital, consisted in medical records analysis: the diagnostic, therapy recommended. Data were scored and statistically analyzed by t test (Windows Excel). The experimental protocol was in agreement with recommendations of the "Gr. T. Popa" University Committee for Research and Ethical Issues.
  
  
  CONCLUSIONS
  Analysis and statistical processing of data shows that during the period of the study, 69 patients, which received oral anticoagulant therapy associated with different other medication belonged to the 60 and 80 years age group. The findings suggests the pathology is represented especially by atrial fibrillation and cerebral ischemic diseases. The correlation between the therapy consisting in OAC and amiodaronum or statines drugs association and International Normalized Ratio (INR), revealed a high level of anticoagulation and an increase of hemorragic complications.
authors.affiliation: Universităţii de Medicină şi Farmacie "Gr. T. Popa" Iaşi.
authors.forename: F
authors.initials: F
authors.lastname: Apostoae
authors.forename: Liliana
authors.initials: L
authors.lastname: Tarţău
authors.forename: Diana
authors.initials: D
authors.lastname: Cimpoeşu
authors.forename: Cătălina Elena
authors.initials: CE
authors.lastname: Lupuşoru
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy; D002545:Brain Ischemia / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004636:Emergency Service, Hospital; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control*; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D017891:Pharmacoepidemiology / Q000379:methods; D012189:Retrospective Studies; D012307:Risk Factors; D012383:Romania; D013997:Time Factors
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000638:Amiodarone